(Reuters) – Swiss drugmaker Roche Holding AG’s Genentech unit said on Monday the U.S. Food and Drug Administration has approved Tecentriq as a standalone therapy for an advanced form of lung cancer.
Tecentriq has won the agency’s approval for use in previously untreated adults with certain types of metastatic non-small cell lung cancer, the company said. (https://reut.rs/2ZcrfxH)
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
